🔗 Share this article

While America proceeds with unprecedented revisions to its vaccine recommendations, one figure has emerged somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots during the pandemic and has zeroed in on alleged fatalities after Covid vaccination in her short position at the FDA.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders planned to reveal major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of step with much of the global community with little proof for benefit. This reveal has been pushed back until the coming year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A New Direction at the Regulatory Body

This interim role might represent a tighter collaboration between the drug and biologics centers as Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US to become more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

Høeg has no obvious background in drug development, regulation or leadership, which has been customary for past leaders of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a large organization. She has no expertise in industry regulation.”

Former directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and every single one need to be managed,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major leadership aspect to the role, which supervises in excess of 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” the former official said.

Response and Contentious Policies

Regarding inquiries about Høeg’s credentials and whether this selection represents more teamwork among agency officials on vaccines, a press secretary stated that the “concerns stem from flawed premises”.

“This background is consistent with the duties of her position,” the spokesperson said, pointing to the period Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s new expedited review system, a contentious expedited medication authorization process that allegedly concerned her preceding directors. “How are these drugs being chosen for this expedited pathway? Who takes the calls?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, aside from vaccines.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if problematic, past, Howard observe. She published a analysis using non-validated public submissions to estimate the incidence of myocarditis following Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current administration featured altering guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has allegedly proposed preventing young men from receiving COVID-19 vaccinations.

“She’s an thorough dogmatist who starts off with her beliefs and tailors the evidence to fit the data in a very disingenuous, fraudulent way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|